Ancient herbs take on stubborn heart pain in seniors

NCT ID NCT07041359

Recruiting now Symptom relief Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two traditional Chinese medicines—Compound Danshen Dripping Pills and Qishen Yiqi Dripping Pills—can reduce chest pain and improve quality of life in elderly patients (75-90 years old) with coronary heart disease who still have symptoms despite standard treatment. 120 participants will receive either one of the herbal pills or a placebo, alongside their usual medications. The goal is to see if these herbs safely ease symptoms like angina and shortness of breath.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Compound Danshen Dripping Pills and Qishen Yiqi Dripping Pills
What this could lead to: If successful, this could provide a safe add-on option to reduce angina symptoms and improve daily life for elderly heart disease patients who still have symptoms despite standard treatment.
What could go wrong: This is a small, early-phase trial (120 participants) focused on symptom relief, not a cure. The benefits may be modest, and results may not apply to all patients. Risks include potential herb-drug interactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERIAL DISEASE (CAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERIAL DISEASE (CAD)

Contacts and locations

Locations

Fuwai hospital, CAMS&PUMC
RECRUITING

Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.